Maynard Um
-
-
-
-
-
-
-
FDA approves Takeda's rusfertide for polycythemia vera treatment
-
-
-
-
-
-
-
Protagonist Therapeutics (PTGX) PT Raised to $165 at Citizens as Icotyde Revenue Ramps
-
-
-
-
-
-
-
Wolfe Research Starts Protagonist Therapeutics (PTGX) at Outperform
-
-
-
-
-
-
-
Jefferies stays Buy on Protagonist Therapeutics (PTGX) amid JNJ's bullish tone on Icotyde
-
-
-
-
-
-
-
Protagonist Therapeutics (PTGX) PT Raised to $121 at Jefferies
-
-
-
-
-
-
-
CORRECTION: Protagonist Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
-
-
-
-
-
-
-
Protagonist and Takeda report 52-week rusfertide data in polycythemia vera
-
444,018 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

